Mei Nuohua: JH389 is a probiotic product, not a medicine, and there are many limitations to its existence as a dietary supplement.

Sina Finance news on March 30th, Novo Nordisk stock trading abnormal fluctuations announcement, the company noted that there are discussions in the market and some channels regarding the company's related research data, clinical trial progress, and future development plans. JH389 is a probiotic product, not a drug, and has many limitations as a dietary supplement. The company's in-research product JH389 is a probiotic, planned to be marketed as a dietary supplement in the future, and is currently in the research trial stage. The sample size for the JH389 probiotic product in domestic trials is 28 cases, a small-scale trial over 8 weeks. Due to the relatively limited sample size, the universality of its conclusions needs further verification in a larger population, and the certainty of its conclusions is not sufficient. Weight reduction non-drug products include probiotic products, other dietary supplements, health foods, meal replacements, and functional foods, competing in various categories. Currently, there are many market participants, with increasing categories, and the industry competition is fierce. In the future, the marketing of JH389 as a dietary supplement, whether it can achieve scale sales, and whether it can generate stable income and profit contributions all have significant uncertainties.